Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Trump Order Reducing Regulation Might Imperil FDA Good Guidance Practices

Executive Summary

Executive order mandating two existing regulations be eliminated for every new one issued includes guidances, raising questions about how FDA will communicate with industry going forward.

You may also be interested in...



OTC Drug Irradiation Rule Exposed As Unnecessary In FDA Regulatory Review

US FDA proposes to repeal regulation that, since 1955, has required an NDA or ANDA for any drug product sterilized by irradiation, including drugs that otherwise would be marketed under an OTC monograph. It notes the Trump administration's order that federal agencies identify and potentially eliminate any unnecessary rules and regulations.

OTC Drug Irradiation Rule Exposed As Unnecessary In FDA Regulatory Review

US FDA proposes to repeal regulation that, since 1955, has required an NDA or ANDA for any drug product sterilized by irradiation, including drugs that otherwise would be marketed under an OTC monograph. It notes the Trump administration's order that federal agencies identify and potentially eliminate any unnecessary rules and regulations.

NPA Submits Wish List For Reducing FDA Regulatory Burdens Per Trump Order

FDA’s NDI notification draft guidance should be rewritten and its Nutrition Facts and Supplement Facts Final Rule delayed, the Natural Products Association says in comments submitted to the agency in response to President Trump’s executive order aimed at cutting down on burdensome regulations.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS119935

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel